<DOC>
	<DOC>NCT00596752</DOC>
	<brief_summary>The study is to confirmatorily show a superior effect of Alprostadil compared to placebo on the rate of complete healing of ischemic necroses and ulcerations as well as on the frequency and height of major amputations in patients suffering from PAOD stage IV.</brief_summary>
	<brief_title>Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV</brief_title>
	<detailed_description />
	<mesh_term>Arterial Occlusive Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Alprostadil</mesh_term>
	<criteria>Subject is at least 45 years of age Subjects with macroangiopathy, proven PAOD Stage IV with up to 2 ischaemic skin lesions for more than 2 weeks Subject has a complete angiography of pelvis, thigh and calf within one month of inclusion Systolic ankle pressure ≤ 70 mmHg in subjects without media sclerosis of the lower limb artery or systolic big toe pressure ≤ 50 mmHg in diabetics with media sclerosis of the lower limb artery Subject is not in the position to be primarily revascularized or refuses surgery Imminent or foreseeable amputation Major amputation on the affected extremity History of chronic alcohol or drug abuse More than two ischemic ulcerations One ulcer ≥ 6 cm^2, both ulcers ≤ 1 cm^2 or at least one ulcer affecting the bone or tendons Acute ischemia and peripheral vascular disorders of inflammatory or immunologic origin Neuropathic or venous ulcers Buerger's disease Septic gangrene Use of vasoactive medication or prostaglandins Treatment with prostanoids within 3 months prior to inclusion Surgical or interventional measures performed on the affected extremity within 3 months prior to study drug treatment</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Alprostadil</keyword>
	<keyword>Prostavasin</keyword>
	<keyword>PAOD</keyword>
	<keyword>Fontaine Stage IV</keyword>
</DOC>